Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Elevance Health Currently Down Nine Consecutive Days, on Track for Longest Losing Streak Since July 2010 -- Data Talk

Elevance Health Currently Down Nine Consecutive Days, on Track for Longest Losing Streak Since July 2010 -- Data Talk

Dow JonesDow Jones2026/09/30 14:21

Elevance Health, Inc. (ELV) is currently at $390.26, down $2.48 or 0.63%

--Would be lowest close since Aug. 17, 2026, when it closed at $390.24

--On pace for largest percent decrease since Sept. 23, 2026, when it fell 0.96%

--Currently down 11 of the past 12 days

--Currently down nine consecutive days; down 5.79% over this period

--Longest losing streak since July 2, 2010, when it fell for nine straight trading days

--Worst nine day stretch since the nine days ending July 27, 2026, when it fell 11.35%

--Down 0.58% month-to-date; on pace for worst month since July 2026, when it fell 2.82%

--Up 11.33% year-to-date

--Down 30.6% from its all-time closing high of $562.29 on Sept. 3, 2024

--Up 17.31% from 52 weeks ago (Oct. 1, 2025), when it closed at $332.66

--Down 8.56% from its 52-week closing high of $426.79 on July 14, 2026

--Up 39.01% from its 52-week closing low of $280.74 on March 9, 2026

--Traded as low as $386.75; lowest intraday level since Aug. 12, 2026, when it hit $385.84

--Down 1.52% at today's intraday low; largest intraday percent decrease since Sept. 22, 2026, when it fell as much as 1.94%

All data as of 10:19:03 AM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

September 30, 2026 10:21 ET (14:21 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56

Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go

Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.

智通财经•2026/10/13 01:36